Cue Biopharma Financial Results
Cue Biopharma reported third quarter 2026 financial results and highlighted the initiation of first-in-human dosing for CUE-401, its first autoimmune therapeutic candidate. The company also shared positive Phase 2 findings for CUE-221 in chronic spontaneous urticaria (CSU), demonstrating statistically significant hives resolution and potential differentiation from existing therapies like Xolair.
- Term
- Q3 2026
“We are seeing exciting momentum across our portfolio. We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy.”
Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma
“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience.”
Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma